CRXM — Gene Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$0.49m
Annual cashflow statement for Gene Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2016 December 31st | 2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.01 | -2.1 | -0.553 | 0.779 | -0.652 |
| Depreciation | |||||
| Non-Cash Items | 0.518 | 0.161 | -0.58 | -1.67 | -0.663 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.452 | 0.807 | 0.618 | 0.696 | 0.18 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -2.02 | -1.06 | -0.452 | -0.137 | -1.13 |
| Capital Expenditures | -0.172 | 0 | — | 0 | -0.003 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | 0.65 | — | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.172 | 0 | 0.65 | 0 | -0.003 |
| Financing Cash Flow Items | 0.104 | -0.031 | -0.195 | -0.1 | -0.371 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.1 | 0.181 | -0.165 | 0.055 | 1.52 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.909 | -0.881 | 0.033 | -0.082 | 0.386 |